Drugs / autologous CD8 T cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07422896 Background | Sep 2026 → Sep 2028 expected | glioblastoma | Catalina Lee Chang | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous CD8 T cells | “a fixed dose of autologous CD8 T cells reinfusion integrated in the standard of care therapy for glioblastoma” NCT07422896 ↗ |
| Modality | Cell therapy | “autologous CD8 T cells reinfusion” NCT07422896 ↗ |